Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urinary Bladder Neck Obstruction 1Triple Negative Breast Neoplasms 1Thrombocythemia, Essential 1Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Prostatic Hyperplasia 1Primary Myelofibrosis 1Polycythemia Vera 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Myeloproliferative Disorders 1Multiple Endocrine Neoplasia Type 1 1Lymphoma, B-Cell 1Lung Neoplasms 1Lower Urinary Tract Symptoms 1Erectile Dysfunction 1Dendritic Cell Sarcoma, Interdigitating 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

Tadalafil 2udenafil 1mirabegron 1bicalutamide 1alpha-Tocopherol 1Vitamin E 1Tamoxifen 1Sildenafil Citrate 1Pentoxifylline 1Long-Term Synaptic Depression 1GPI 1485 1Erythropoietin 1Dutasteride 1Atorvastatin 1Arginine 1ArginMax 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Erectile Dysfunction × mirabegron × Clear all
NCT03600766 2019-09-04

Mirabegron for Treatment of Erectile Dysfunction in Patients With LUTS Secondry to BPH: A Randomized Study

Mansoura University

Phase 2 Unknown
50 enrolled
Genitourinary

Erectile Dysfunction, Prostatic Hyperplasia, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡